Cytokinetics, Incorporated

What they do

Cytokinetics discovers and develops small-molecule drugs that modulate muscle function. Its first commercial product, MYQORZO (aficamten), was approved by the FDA in December 2025 for obstructive hypertrophic cardiomyopathy and launched in the U.S. in January 2026. The company also has a pipeline including aficamten in non-obstructive HCM and omecamtiv mecarbil for heart failure, and it runs clinical trials and receives collaboration revenue from partners like Bayer and Sanofi.

Revenue drivers

• MYQORZO product sales — Net product revenue in Q2 2026 was $25 million, contributing to total quarterly revenue of $28.6 million. As of June 30, 2026, over 1,500 patients were dispensed MYQORZO and over 80% of patients on therapy had paid prescriptions.
• License and milestone revenues — In 2025, license and milestone revenues were $79.4 million, including $52.4 million from Bayer for technology transfer completion, $11.8 million for clinical milestones, and $15.0 million from Sanofi triggered by approvals in the U.S. and China.
• Collaboration revenues — Collaboration revenues were $8.7 million in 2025, primarily from Bayer for research and development cost reimbursements under the Bayer License Agreement.

Recent performance

Revenue in Q2 2026 was $28.6 million, up from $17.8 million in Q4 2025 and $19.4 million in Q1 2026. Product sales drove the growth, with MYQORZO net product revenue of $25 million in Q2. Full-year 2025 revenue was $88.1 million, almost entirely from license and milestone revenues, up from $18.5 million in 2024. Operating cash flow was negative $510.0 million in 2025, and the company held cash, cash equivalents and investments of ~$1.7 billion at June 30, 2026, despite a shareholder deficit of $173.5 million.

Strategy

Cytokinetics aims to build a global specialty cardiology franchise around MYQORZO, focusing on commercial launch expansion and market access in U.S. and international markets. It plans to advance aficamten into non-obstructive HCM, with a supplemental NDA expected in Q4 2026. The company is also developing omecamtiv mecarbil for heart failure and earlier-stage muscle-directed candidates. Management intends to leverage its myosin platform to achieve two product approvals across three indications and add 10 novel molecular entities to the pipeline by 2030.

Risks

• Commercial adoption risk — Physicians and patients may not accept MYQORZO due to competition, reimbursement issues, or side effects, limiting revenue growth.
• Clinical trial failure risk — Phase 3 trials, including ACACIA-HCM for nHCM and COMET-HF for omecamtiv mecarbil, may not meet endpoints or gain regulatory approval.
• Financial sustainability risk — The company has negative shareholder equity, recurring operating losses, and negative operating cash flow, requiring continued capital raises.
• Regulatory and reimbursement risk — MYQORZO requires a REMS program, and reimbursement approvals in international markets remain uncertain, affecting sales.

Outlook

Management expects to present full results from ACACIA-HCM at ESC in August 2026 and submit a supplemental NDA for aficamten in nHCM in Q4 2026. They plan to launch in more than five additional European markets by the first half of 2027, with regulatory reviews ongoing in Canada, Switzerland, Hong Kong and Taiwan. The company secured additional capital in Q2 2026 and believes it has resources to support commercialization and pipeline development.